Inflammatory Bowel Diseases
Conditions
Keywords
Crohn's disease, ulcerative colitis, Syndecan-1
Brief summary
Syndecan-1 is a protein on the surface intestinal cells. previous studies proved low levels of mucosal syndecan-1 levels on the surface of intestinal cells is patients with acute and chronic inflammation due to inflammatory bowel disease. this protein might shed from cell surface to the serum. The investigators wish to prove that elevated serum levels of syndecan-1 may be predictive of disease presence, extent and severity, that buy taking a simple blood sample from patients diagnosed with inflammatory bowel disease and comparing to normal subjects and to other markers.
Detailed description
One of the main hypothesis for the etiology of Inflammatory bowel disease (IBD) is an inappropriate and ongoing activation of the mucosal immune system in response to the presence of normal luminal flora. This aberrant response is most likely facilitated by defects in both the barrier function and the mucosal immune system of the intestinal epithelium. Syndecans are a class proteoglycans that take part in both cell adhesion and growth factor binding. Of the four known syndecan core proteins, syndecan-1 (CD138) and one of the best studied of this group and is also the relevant to the this study as it is expressed on the basolateral surface of columnar epithelial cells of the colon. Syndecan-1 functions as an integral membrane protein that participates in cell proliferation, cell migration and cell matrix interactions in the GI tract. Evidence for a reduction of syndecan-1 expression in the regenerating epithelium that overlies inflamed tissue was reported in both acute and chronic inflammation. This protein that is lost from the inflamed mucosal membrane might shed to the serum. Elevated serum levels of syndecan-1 may be predictive of disease presence and extent.
Interventions
PROCEDUREblood sample
Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
PROCEDUREBlood sample - venous blood 10 ml.
venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
Sponsors
Meir Medical Center
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* informed consent * no other concurrent inflammatory disease * formal diagnosis of inflammatory bowel disease i.e Crohn's disease, Ulcerative colitis
Exclusion criteria
* pregnancy * fever at time of sample taking
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Elevated serum syndecan-1 levels as a bio marker for IBD | one year | elevated serum syndecan-1 levels in patients with IBD compared to control |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum syndecan-1 levels and disease severity Crohn's | one year | Relationship between clinical data CDAI in crohn's patients and serum syndecan-1 levels |
| Serum syndecan-1 levels and disease severity ulcerative colitis | one year | Relationship between clinical data UCAI ulcerative colitis patients and serum syndecan-1 levels |
| Serum syndecan-1 levels and C reactive protein(CRP) Crohn's | one year | Relationship between lab data CRP levels in crohn's patients and serum syndecan-1 levels |
| Serum syndecan-1 levels and C reactive protein(CRP) ulcerative colitis | one year | Relationship between serum CRP levels and serum syndecan-1 levels in patients with ulcerative colitis |
Countries
Israel
Outcome results
None listed